Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 81CNS 33Gynecologic 26Thoracic 25Genitourinary 19Other solid neoplasm 14Breast 13Sarcoma 9Dermatologic 8Head & Neck 6Tumor-Agnostic 5Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

fludarabine phosphate 12Whole-Body Irradiation 11Peripheral Blood Stem Cell Transplantation 11Cyclophosphamide 11Mycophenolic Acid 9fludarabine 7Cyclosporine 6Busulfan 6Tacrolimus 4Melphalan 4Filgrastim 4Cytarabine 4Cord Blood Stem Cell Transplantation 4Antilymphocyte Serum 4eltrombopag 3Flow Cytometry 3Cytogenetic Analysis 3Cyclosporins 3Alemtuzumab 3AP 1903 reagent 3romiplostim 2Transplantation 2Topotecan 2Thiotepa 2Sirolimus 2SRA737 2Radiotherapy 2Gene Expression Profiling 2Etoposide 2Decitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Bevacizumab × Classical hematology × Clear all
NCT00022048 2013-05-15

Bevacizumab in Treating Patients With Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 1/2 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡